- cafead   Sep 12, 2023 at 12:02: PM
via A tiny slice of early-stage data for AstraZeneca’s Daiichi Sankyo-partnered antibody drug conjugate showed a high objective response and disease control rate when combined with immune checkpoint inhibitor Imfinzi in patients with non-small cell lung cancer. (NSCLC).
article source
article source